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Abstract
Background and Methodology: Recently, we reported on a new class of naphthoquinone derivatives showing a promising
anti-trypanosomatid profile in cell-based experiments. The lead of this series (B6, 2-phenoxy-1,4-naphthoquinone) showed
an ED50 of 80 nM against Trypanosoma brucei rhodesiense, and a selectivity index of 74 with respect to mammalian cells. A
multitarget profile for this compound is easily conceivable, because quinones, as natural products, serve plants as potent
defense chemicals with an intrinsic multifunctional mechanism of action. To disclose such a multitarget profile of B6, we
exploited a chemical proteomics approach.
Principal Findings: A functionalized congener of B6 was immobilized on a solid matrix and used to isolate target proteins
from Trypanosoma brucei lysates. Mass analysis delivered two enzymes, i.e. glycosomal glycerol kinase and glycosomal
glyceraldehyde-3-phosphate dehydrogenase, as potential molecular targets for B6. Both enzymes were recombinantly
expressed and purified, and used for chemical validation. Indeed, B6 was able to inhibit both enzymes with IC50 values in
the micromolar range. The multifunctional profile was further characterized in experiments using permeabilized
Trypanosoma brucei cells and mitochondrial cell fractions. It turned out that B6 was also able to generate oxygen radicals,
a mechanism that may additionally contribute to its observed potent trypanocidal activity.
Conclusions and Significance: Overall, B6 showed a multitarget mechanism of action, which provides a molecular
explanation of its promising anti-trypanosomatid activity. Furthermore, the forward chemical genetics approach here
applied may be viable in the molecular characterization of novel multitarget ligands.
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Introduction
Among the tropical diseases, there are maladies whose
etiological agents belong to the Trypanosomatidae family of the
Protista, order Kinetoplastea, that are responsible for infections
concentrated in the poorest, mainly rural areas of the planet, and
that are grouped under the name of ‘‘most neglected diseases’’ [1].
In particular, parasites of the genus Trypanosoma are responsible for
Chagas’ disease in Latin America and sleeping sickness in sub-
Saharan Africa [2–5]. Because of their occurrence in low-income
and middle-income countries, these diseases do not have high
visibility in Western societies, although sleeping sickness is among
the neglected tropical diseases with the highest rates of death [6].
Vaccine development has been hampered by either the high
degree of antigenic variation as exhibited by the bloodstream
dwelling African trypanosome, Trypanosoma brucei, and the local-
ization of the American trypanosome, Trypanosoma cruzi, within
cells of the human host, despite a successful experimental oral
vaccine based on attenuated T. cruzi has been reported [7]. In this
context, chemotherapy still represents a viable option for
treatment of these infections [8]. However, the majority of the
currently available drugs are decades old (some back to 1920) and
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have, unfortunately, many limitations, including high toxicity and
the emergence of drug resistance. The latter issue has called for
designing innovative approaches to drug discovery for infections
by trypanosomes [9,10]. A major role in this respect is played by
combination therapy, which has been shown to be a possible
strategy for both preventing and overcoming chemotherapy-
induced resistance [11]. A logical alternative to combination
therapy is the development of drugs able to hit multiple targets
[12,13]. Such multitarget compounds are single chemical entities
that can provide the same pharmacological profile as drug
combinations, but potentially with fewer side effects. In fact, when
two or more drugs are administered as a combination, there is a
possibility that the drugs may interact with each other (drug-drug
interaction). This interaction could increase or decrease the
effective concentration of one of the drugs or, more frequently,
could even enhance the adverse effects. Indeed, single multitarget
compounds have a much simpler pharmacokinetic profile than
combination therapy, also prevent possible side effects due to
drug-drug interactions, greatly simplify the therapeutic regimen,
with positive consequences for patient adherence and caregiver
compliance, and finally an overall improved selectivity. Further-
more, the easier and cheaper manufacturing and formulation of a
single active pharmaceutical ingredient would make multitarget
drugs inherently more cost-effective and widely accessible than
combinations [14].
It should be mentioned that if there is any synergism or additive
effect among the targets, then the effective dosage of a multitarget
drug is most likely lower than that of a single-target drug. When
lowering the therapeutic dose, however, it will be crucial to find a
balance between decreasing the dose to avoid side effects and
keeping it sufficiently high to prevent the development of
resistance. On these premises, it has been proposed that against
trypanosomatid-borne diseases such compounds may prove more
efficacious, tolerable, and affordable than the available arsenal of
drugs [12,15].
Naphthoquinone and other quinone derivatives have been
reported as one of the major natural product classes with
significant activity against Trypanosoma [16–18]. For instance,
lapachol exhibits a marked anti-trypanosomal profile, while
displaying no serious toxic effects in humans [19]. In view of the
well-known biological properties of this class of compounds, it is
highly possible that naphthoquinones exert their anti-trypanoso-
matid profile by means of a multitarget mechanism. Indeed, a
multitarget profile for this class of compounds is easily conceivable,
because quinones, like many other natural products, provide
plants with potent defense chemicals with an intrinsic multifunc-
tional mechanism of action [20]. Furthermore, it can be
hypothesized that in addition to a possible target-related mech-
anism, the general free-radical-generation mechanism of quinones
– probably also at the basis of their general cytotoxicity – may
contribute to multitarget profile of these molecules [21] [22].
Indeed, it has been reported in the literature that parasitic protists
are particularly sensitive to oxidative stress [23].
In this field, we have recently reported on the preparation of a
focused library of 16 compounds based on the 1,4-naphthoqui-
none and 1,4-anthraquinone natural occurring scaffolds [24].
From this small compound collection, several molecules were
active against Trypanosoma and Leishmania at low concentrations.
Some of the derivatives exhibited potency in the nanomolar range,
with one (2-phenoxy-1,4-naphthoquinone, B6 in Figure 1) dis-
playing an ED50 value of 80 nM against Trypanosoma brucei
rhodesiense, as assessed in experiments using in vitro cultured
parasites. It also showed a selectivity index (ratio of the
compound’s ED50 values on mammalian cell lines and trypano-
somes) of 74 [24], which is very close to the specifications required
by WHO/TDR to be considered an anti-trypanosomatid hit [25].
However, the molecular mechanism and the target(s) responsible
for the biological profile of this class of compounds have remained
undisclosed.
Here, by means of a chemical proteomics approach, we aimed
at identifying the putative molecular target(s) of B6. In particular,
using its immobilized derivative 1 (Fig. 1), we isolated its targets
from parasite extracts. Then, by means of biochemical experi-
ments, we verified the ability of the molecule to bind to
recombinant forms of the identified targets. In light of the general
property of naphthoquinones to generate free radicals, we finally
analyzed oxygen consumption in permeabilized trypanosomes and
production of reactive oxygen species (ROS) in trypanosome
mitochondrial cell fractions. This allowed us to elucidate
additional B6 potential mechanisms of action, as chemical
proteomics is not suited to identify non-protein targets.
Methods
Chemical synthesis and anti-trypanosomal activity of B6-
derivatives 1–3
Before covalently attaching B6 to the solid support through a
linker, we analyzed which site(s) of the molecule were more
appropriate for linking purposes. To this end we synthesized
derivatives 1–3 (Fig. 1), which carry in different positions amino or
hydroxyl groups that can be easily exploited as anchor points. The
synthesis was carried out according to the procedure reported for
B6 [24], and which relies on the substitution of a 2-bromo-
naphthoquinone with the corresponding phenol.
Synthesis of 2-(4-amino-phenoxy)-[1,4]naphthoquinone (1). To a stirred
solution of 4-amino-phenol (0.46 g, 4.2 mmol) in 90 ml dimethyl-
formamide (DMF) potassium carbonate (1.70 g, 12.3 mmol) was
added. After stirring for 1 h at room temperature, 2-bromo-[1,4]-
naphthoquinone (1.0 g, 4.2 mmol) was added. After stirring for
further 3 h, the reaction was diluted with water and ice (500 ml)
and the resulted brownish solid was collected by filtration to give
0.49 g of crude 1, which was crystallized by EtOH/water (40%
yield). IR (Nujol) 3421, 3382, 1680, 1635, 1609, 1508, 1204, 980,
718 cm21; 1H NMR (300 MHz, CDCl3) d 8.25-8.22 (m, 1H),
8.12-8.09 (m, 1H), 7.80-7.78 (m, 2H), 6.95 (d, 2H, J = 8.5 Hz),
Author Summary
The multitarget approach can represent a promising
strategy for the discovery of innovative drug candidates
against neglected tropical diseases. However, multitarget
drug discovery can be very demanding, because of the
highly time-consuming step related to the fine balancing
of the biological activities against selected targets. An
innovative workflow for discovering multitarget drugs can
be envisioned: i) design and synthesis of natural-like
compounds; ii) test them using phenotypic cell-based
assays; iii) fishing potential targets by means of chemical
proteomics. This workflow might rapidly provide new hit
candidates that can be further progressed to the hit-to-
lead and lead optimization steps of the drug discovery
process. The two latter steps can benefit from information
on the molecular target(s), which may be identified by
chemical proteomics. Herein, we report on the elucidation
of the mode of action of a new series of anti-trypanosomal
naphthoquinone compounds, previously tested using cell-
based assays, by means of chemical proteomics, classical
biochemistry, molecular and system biology.
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6.76 (d, 2H, J = 8.5 Hz), 6.04 (s, 1H), 3.77 (br s, 2H, exchangeable
with D2O); HRMS (ES) m/z calculated for C16H11NO3Na
288.0637, found 288.0639 [M++Na+].
Synthesis of 5-hydroxy-2-phenoxy-[1,4]naphthoquinone (2). It was
synthesized in 33% yield from phenol and 2-bromo-5-hydroxy-
[1,4]-naphthoquinone, following the procedure reported for 1 and
crystallization from methylene chloride/petroleum ether. 1H-
NMR (CDCl3, 400 MHz): d 5.88 (s, 1H), d 7.13 (d, J= 8.4, 2H), d
7.26-7.35 (m, 2H), d 7.47 (t, J= 7.6, 2H), d 7.61 (t, J= 8.0, 1H), d
7.74 (d, J= 7.2, 1H), d 12.10 (s, exch, 1H); 13C-NMR (CDCl3,
400 MHz): d 113.17, 114.40, 119.91, 121.22, 125.56, 127.03,
130.70, 131.30, 135.90, 152.77, 161.30, 161.34, 179.43, 191.07;
MS (ESI+) m/z:289 [M++Na+].
Synthesis of 8-hydroxy-2-phenoxy-[1,4]naphthoquinone (3). It was
synthesized in 35% yield from phenol and 2-bromo-8-hydroxy-
[1,4]-naphthoquinone, following the procedure reported for 1 and
crystallization from methylene chloride/petroleum ether. 1H-
NMR (CDCl3, 400 MHz): d 5.94 (s, 1H), d 7.13 (d, J= 8.8, 2H), d
7.26-7.34 (m, 2H), d 7.47 (t, J= 7.6, 2H), d 7.59-7.67 (m, 2H), d
11.79 (s, exch, 1H); 13C-NMR (CDCl3, 400 MHz): d 114.18,
119.22, 121.22, 124.30, 126.98, 130.70, 132.20, 137.48, 152.77,
160.38, 162.25, 184.25; MS (ESI+) m/z:289 [M++Na+].
The synthesized compounds were then tested against T. b.
rhodesiense parasites as previously reported [24], and their activities
are shown in Figure 1 along with that of B6. Because of its superior
trypanocidal activity, 1 was selected for further immobilization
studies.
Preparation of parasite lysates
For identification of the B6 targets, T. b. rhodesiense was used.
The parasites were isolated from blood of an infected mouse
(received from the Swiss Tropical and Health Institute, Basel,
Switzerland). Parasite lysates were prepared as described previ-
ously [26]. Briefly, 56108 cells were lysed in 200 ml lysis buffer
consisting of 160 ml PBS (38 mM Na2HPO4, 2 mM NaH2PO4,
29 mM NaCl, pH 8.0) containing 44 mM glucose and 40 ml of
lysis buffer concentrate (100 mM HEPES, pH 7.5, 750 mM
NaCl, 5% Triton-X-100, 10 mM tris(2-carboxyethyl)phosphine
(TCEP), 50% glycerol, and 1 ml/ml protease cocktail (Sigma).
After short periods of sonication the mixture was centrifuged for
10 min at 14,000 g, the supernatant was recovered and stored in
aliquots of 100 ml at 280uC, until needed. The protein
concentration, determined using the Bradford dye assay with
BSA as reference protein, was found to be 8.4 mg/ml.
Affinity chromatography and protein identification by
mass spectrometry
1 was immobilized to epoxy-activated Sepharose 6B using a
modified protocol described earlier [26]. To this end, swollen and
thoroughly washed matrix was resuspended in two volumes of
35 mM ligand dissolved in a solution containing 50% dioxane/
50% H2O (solution 1). Coupling was performed for 48 h at 40uC
using 40 ml of swollen resin mixed with 80 ml of ligand solution.
After coupling, the matrices were centrifuged for 1 min at 3000 g,
and then washed 4–5 times with 10 volumes (400 ml) of solution 1.
Afterwards, remaining free epoxides were reacted by adding 1 ml
of a solution containing 50% dioxane and 50% acetic acid
(pH 3.2) and incubation for 20 h at 40uC. After incubation, the
samples were centrifuged at 3000 g for 2 min and the supernatants
collected. The resin was finally washed in five rounds, each with 10
volumes of solution 1. Again all supernatants were collected.
Supernatants of all steps were collected in a 25.0 ml volumetric
flask and used to determine the amount of ligand washed off.
Direct absorbance of the scans of the immobilized ligand on the
matrix resuspended in 50% glycerol solution (v/v) clearly
confirmed successful coupling (data not shown). The amount of
inhibitor bound to the matrix was determined by back calculation
of the amount of compound applied and amount recovered.
Routinely 2–3 mmol/ml of compound were bound. A control
matrix was prepared without ligand and treated as described
above.
Before incubation with the lysate the matrices were washed
twice with water and then equilibrated in the lysate buffer by
washing each resin three times with the lysate buffer. The lysate
(100 ml; diluted to 2.1 mg/ml protein using PBS) was incubated
with the ligand-bound matrix for 2 h at 4uC while mixing at
700 rpm. Then, the matrix was washed 5 times with the lysate
buffer while mixing for 90 sec at 1400 rpm. The control matrix
was incubated with the same amount of lysate and treated equally.
Finally, both matrices were washed with a solution containing
5 mM HEPES (pH 7.0) and sent to the Functional Genomics
Center of Zurich for protein identification directly from the
matrices. To this end, resins were re-suspended in 50 ml trypsin
solution (10 ng/ml trypsin in 10 mM Tris-HCl, 2 mM CaCl2,
pH 8.2) and incubated at 37uC overnight. Supernatants were
separated and beads extracted twice with 5% formic acid in 10%
acetonitrile. All three supernatants of the corresponding matrices
were combined, dried, and then dissolved in 25 ml 0.1% formic
acid. 2 ml were injected via an autosampler and run with two
different gradients (A and B) for LC/ESI/MS/MS-QTOF
Figure 1. Chemical structures. Chemical structure and activity against Trypanosoma brucei rhodesiense parasites of B6 and derivatives 1–3
synthesized for immobilization studies.
doi:10.1371/journal.pntd.0002012.g001
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analysis. Database searches were performed by using the
ProteinLynx Global Server (Swiss Prot, all species) and Mascot
(Swiss Prot, excluding the major eukaryotic species from the
search) search programs. Only hits with enough independent
peptide spectra to give a probability of over 95% were considered
for the study.
Expression and purification of Trypanosoma brucei brucei
glycerol kinase
The expression construct has been obtained by subcloning the
corresponding GK gene (isolated from T. b. brucei strain Lister 427)
from the formerly designed pET15-TbGK plasmid [27] into
vector pET28 to create the final expression plasmid pET28-
TbGK (unpublished data). TbGK was then expressed in E. coli
BL21(DE3)-CodonPlus-RIL grown in 1 liter LB medium supple-
mented with kanamycin (50 mg/ml) and chloramphenicol (34 mg/
ml) for 16 h at 37uC. Expression was induced by adding 1 mM
isopropyl b-d-thiogalactanopyranoside (IPTG), and growth was
continued for another 2 h at 37uC. Bacteria were harvested
(20 min, 4uC, 5000 rpm), resuspended in a mixture of 96% buffer
A (20 mM Tris-HCl, 200 mM NaCl, pH 7.6) and 4% buffer B
(20 mM Tris-HCl, 200 mM NaCl, 500 mM imidazole, pH 7.6),
and supplemented with a small amount of DNase. The suspension
was passed twice through a French Press, centrifuged (20 min,
4uC, 9800 rpm), and the clarified crude extract was applied onto a
5 ml Ni-chelating column. TbGK was eluted using a 10 column
volumes linear imidazole-gradient using buffer A and buffer B.
Eluted fractions were analyzed by SDS-PAGE. Fractions contain-
ing TbGK were combined, supplemented with 2 mM CaCl2 and
10 U/ml thrombin to cleave off the histidine tag. After overnight
incubation at 16uC, the digested protein was concentrated and
desalted using a Superdex 75 column equilibrated with buffer A.
Protein concentration was determined at 280 nm (extinction
coefficient = 81650 M21 cm21). The protein was diluted to a
concentration of 2 mg/ml and stored at 4uC.
T. b. brucei glycerol kinase assay
The TbGK activity was measured using a modified version of a
continuous enzyme-coupled spectrophotometric assay developed
previously [28]. Briefly, the ATP consumption associated with
glycerol phosphorylation was coupled to the oxidation of NADH
via the coupled pyruvate kinase/lactate dehydrogenase enzyme
pair. The assays were performed in 1.0 ml triethanolamine/HCl
buffer (0.1 M triethanolamine, 2.5 mM MgSO4, 10 mM KCl,
5 mM glycerol, 0.1 mM ATP, 2.2 mM phosphoenolpyruvate,
0.1% DMSO, pH 8.0), at 25uC in the presence of 5 U pyruvate
kinase, 3 U lactate dehydrogenase, and 150 ng TbGK. The
concentration of B6 was varied in the range of 1 nM to 10 mM.
The reaction was started by adding 0.42 mM NADH. The IC50
value of B6 was calculated as the mean of three independent
experiments.
Expression and purification of T. b. brucei glyceraldehyde-
3-phosphate dehydrogenase
T. b. brucei glyceraldehyde-3-phosphate dehydrogenase
(TbGAPDH) was expressed using expression vector pET28a
carrying the GAPDH gene which had been subcloned from a
former expression clone (T. b. brucei strain Lister 427) based on
pET3a [29] using NdeI and BamHI restriction enzymes (unpub-
lished results).
A culture of E. coli strain BL21(DE3) harboring an expression
plasmid with TbGAPDH was grown at 37uC in 100 ml of LB
medium. When the OD at 600 nm was between 0.5 and 0.8,
expression was induced by addition of 1 mM IPTG. Growth was
continued overnight. TbGAPDH was purified essentially as above
reported for TbGK with the only difference that the clarified
crude extract was applied onto a Talon resin column (Talon,
Clontech), and that the protein of interest was eluted with
200 mM imidazole. TbGAPDH was identified by SDS-PAGE and
Coomassie blue staining.
T. b. brucei glyceraldehyde-3-phosphate dehydrogenase
assay
The kinetics of the TbGAPDH reaction was monitored using a
continuous enzyme-coupled spectrophotometric assay, as previ-
ously described [29]. In brief, TbGAPDH activity was measured
following the NADH oxidation at 340 nm, in a coupled assay with
3-phosphoglycerate kinase and using a Jasco V-550 spectropho-
tometer.
All measurements were performed at 25uC in 0.01 M trietha-
nolamine, pH 7.6, 1.7 mM ATP, 1 mM EDTA, 100 mM KCl,
5 mM MgSO4, 1.7 mM NaHCO3, 25 mg 3-phosphoglycerate
kinase. The IC50 values were determined in a final volume of 1 ml
in the presence of 120 ng TbGAPDH and 5.6 mM 3-phospho-
glycerate (3-PGA), while varying the B6 concentration after a pre-
incubation of enzyme plus inhibitor for 10 min. The reaction was
started by the addition of 0.2 mM NADH. Each point of the curve
was measured in triplicates and the value for IC50 was estimated
from graphically plotted dose-response curves.
The type of inhibition was determined with respect to NADH
and 3-PGA in consideration of Michaelis-Menten steady-state
conditions. To investigate the inhibition mechanism with respect
to NADH, TbGAPDH was incubated for 10 min at room
temperature with different inhibitor concentrations (0–15 mM) in
a total volume of 1 ml. The reaction was initiated by the addition
of 5.6 mM 3-PGA and NADH (ranging from 5 mM to 200 mM).
The inhibition mechanism with respect to 3-PGA was determined
in a similar way. To this end, TbGAPDH was incubated with
varying inhibitor concentrations (10 nM–100 mM). The reaction
was initiated by the addition of 0.2 mM NADH and 3-PGA
(ranging from 50 mM to 5.6 mM). The a and Ki values were
obtained from Dixon and secondary plots. The reported values
represent the mean of two independent experiments.
Mathematical modeling
For a comprehensive analysis of the effect of simultaneous
inhibition of GAPDH and GK on the glycolytic flux by B6, we
used a mathematical model.
Modeling was done with the T. brucei glycolysis model [30] in
the open-source software package PySCeS [31] with Python 2.6.
In the model version used here, the equations for the cytosolic and
glycosomal adenylate kinases were replaced with mass action
kinetics consistent with the equilibrium constant of 0.442 mM
[32], the glycerol-3-phosphate oxidase (GPO) has access to the
glycosomal pools of glycerol-3-phosphate (G3P) and dihydroxyac-
etone phosphate and phosphoglycerate mutase has access to the
glycosomal pool of 3-PGA. These adjustments hardly affected
control distribution and the glycolytic flux in this version of the
model is equally sensitive to glycerol inhibition at anaerobic
conditions as the model described in [30]. To simulate titration of
a non-competitive inhibition, the Vmax of GAPDH and/or GK was
multiplied by
1
1z
½I 
Ki
, using a Ki for GAPDH of 4 mM (based on
measurements in this paper: 3.6 or 5.0 mM depending on the
substrate that was varied) and for GK 0.90 mM (as reported in this
paper). To simulate anaerobic conditions, the Vmax of the short
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mitochondrial respiratory chain (in the model referred to as GPO,
consisting of a mitochondrial FAD-dependent glycerol-3-phos-
phate dehydrogenase, ubiquinone and the alternative oxidase
(TAO)) was set to zero.
Preparation of a mitochondria enriched cell fraction
Bloodstream- and procyclic-form T. b. brucei cells (strain Lister
427, cell line 449) were cultured up to the exponential growth
phase and homogenates were obtained by grinding the washed
parasite pellets with silicon-carbide abrasive grain (mesh 300) in
disruption buffer containing 250 mM sucrose, 25 mM Tris-HCl
and l mM EDTA, pH 7.8 (STE buffer). Differential centrifugation
[33] was performed as follows: the suspension was taken up in
another 3 ml STE buffer and centrifuged at 30 g for 3 min. The
supernatant, representing the cell homogenate, was centrifuged at
1,500 g for 10 min giving the nuclear fraction. The post-nuclear
supernatant was then centrifuged at 5,000 g for 10 min giving the
large-granular (mitochondria-enriched) fraction as pellet. This
fraction was resuspended in 300 ml STE buffer.
Oxygen consumption measurements
Oxygen consumption was monitored in a thermostated vessel at
37uC with a Clark electrode (oxygraph). Measurements in
permeabilized bloodstream-form T. brucei were done in buffer 1
(96.9 mM NaCl, 3.1 mM KCl, 5 mM MgCl2, 2 mM Na2HPO4,
90 mM Tris at pH 7.5). Batches of 26107 cells were pelleted,
washed in buffer 1 and incubated for 59 on ice in 1 ml of buffer 1
containing 1 ng digitonin to permeabilize the cells. Subsequently
the permeabilized cells were pelleted and washed twice with buffer
1 without digitonin after which the pellet was taken up in 1 ml
buffer 1 and transferred to the oxygraph. Substrates and inhibitors
were added as described in the text.
2 mM salicylhydroxamic acid (SHAM) was used to completely
inhibit the T. b. brucei alternative oxidase (TAO) that is part of the
GPO. B6 and SHAM were dissolved in DMSO. The DMSO
concentration used in these oxygen consumption measurements
was less than 0.7%.
Measurement of hydrogen peroxide production
The method used to measure H2O2 production in T. b. brucei
mitochondria is based on the fluorogenic probe 29,79-dichlorodi-
hydrofluorescein diacetate (H2DCFDA) which emits an intense
green fluorescence only after deacetylation and subsequent
oxidation. ROS production by the mitochondrial fraction of
bloodstream form T. b. brucei was measured in a 96-well microtiter
plate using a fluorescence plate reader (Victor Wallace multiplate
reader).
In each well, 0.25 mg mitochondrial protein/ml and 5 mM
H2DCFDA to a final volume of 0.2 ml with 10 mM Tris-HCl,
50 mM KCl, 1 mM EDTA, pH 7.5 were present. The reaction,
performed at 25uC, was started by the addition of 10 mM G3P, in
the presence and absence of 10 mM B6.
T. b. brucei growth conditions
We used bloodstream and procyclic forms of T. b. brucei strain
Lister 427, cell lines 449 [34], constitutively expressing the E. coli
tetracycline (Tet) repressor gene via the chromosomally integrated
plasmid pHD449 that also confers phleomycin resistance. Blood-
stream forms were cultured in HMI-9 medium containing 10%
heat-inactivated foetal calf serum (Invitrogen) and 0.18 mg/ml
phleomycin (Cayla) at 37uC under water-saturated air with 5%
CO2. Procyclic trypanosomes were grown in SDM79 medium
[35] supplemented with 15% foetal calf serum and 0.5 mg/ml
phleomycin at 28uC under water-saturated air with 5% CO2. The
glucose-depleted SDM-80 medium, first employed by Lamour et
al. [36], was supplemented with 5 mg/ml hemin, 9% (v/v) dialyzed
‘‘glucose free’’ heat-inactivated foetal calf serum (Sigma) and 1%
(v/v) of normal heat-inactivated foetal calf serum (Invitrogen).
Growth inhibition tests of trypanosomes
T. b. rhodesiense in vitro growth inhibition activity of 1–3 (Fig. 1)
was assessed using bloodstream form of STIB 900 strain, following
the procedure reported in Orhan et al. [37].
The anti-trypanosomal activity tests were also performed on T.
b. brucei according to the ‘‘Long Incubation Low Inoculation Test’’
(LILIT) [38,39] using cultured bloodstream and procyclic forms of
T. b. brucei strain Lister 427, cell line 449 [34].
It should be noted that T. b. rhodesiense, used in the initial
inhibition activity assays, and T. b. brucei, used in all molecular and
biochemical studies and in some growth inhibition assays
performed at a later stage, are different subspecies that at the
molecular level are almost identical. The essentially only difference
is that the former subspecies is human pathogenic, due to
resistance to a lytic factor present in human serum, whereas the
latter subspecies is susceptible to the lytic factor. In addition,
variable expression levels of proteins may give rise to differences in
drug susceptibilities between subspecies.
Docking simulations
Docking of B6 was carried out using the crystal structure of
TbGAPDH (PDBid: 2X0N) [40]. The binding pocket was defined
as 10 A˚ from Cys166. Tautomeric states of histidines and the
positions of asparagine and glutamine side chain amidic groups
were optimized to improve the hydrogen bonding pattern. Polar
hydrogen atoms were also optimized. The adopted force field was
a modified version of the ECEPP/3 force field [41]. B6 was
assigned the MMFF force field atom types and charges [42].
Docking simulations were carried out by means of the Biased
Probability Monte Carlo stochastic optimizer as implemented in
ICM [43,44]. The molecular conformation of the system was
described by means of internal coordinate variables. The other
binding site residues were represented by pre-calculated 0.5 A˚
spacing potential grid maps, representing van der Waals potentials
for hydrogens and heavy atoms, electrostatics, hydrophobicity,
and hydrogen bonding, respectively. The van der Waals interac-
tions were described by a smoother form of the 6–12 Lennard-
Jones potential with the repulsive contribution capped at a cutoff
value of 4 kcal/mol. Poses from Monte Carlo sampling were
rescored by means of the standard ICM empirical scoring function
[45].
Results
Compound choice and immobilization
A typical target isolation project begins with structure-activity
relationship (SAR) studies, in which various portions of the small
molecule of interest are modified to determine which one(s) can be
used as points of attachment to a solid matrix [46]. It is important
to note that several small molecules that have no sites appropriate
for modification are not suited for affinity-based target isolation
[47]. In our case, we successfully modified B6 to accommodate
functional groups through which it could be covalently linked to
the resin. We investigated three positions for the introduction of
reactive amino or hydroxyl groups: one on the phenoxy moiety
(compound 1) and two on the napthoquinone portion (compounds
2 and 3) (Fig. 1). Subsequent biological studies showed that the
chemical modifications performed on B6 resulting in 1 and 3 did
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not have a dramatic impact on the observed anti-Trypanosoma
profile. Conversely, 2 showed a significant decrease of the
trypanocidal activity (Fig. 1). In particular, as 1 was only 7 times
less active than B6, we assumed that 1 might retain B6-like binding
properties. Thus, we next performed affinity chromatography and
target identification studies using 1.
Chemical proteomics and bioinformatics analysis
A T. b. rhodesiense lysate was prepared as described in the
Methods section, and 1 was immobilized on an affinity chroma-
tography column. After LC separation using two gradients and
subsequent mass spectrometry and database searches, four
trypanosome proteins were identified with a probability of more
than 95%, and which were found only on the coupled matrix but
were absent in the control experiment (Table S1): i.e., (i)
glycosomal glycerol kinase (TbGK; SwissProt accession code
Q9NJP9), (ii) tubulin beta chain (P04107), (iii) tubulin alpha chain
(P04106), and (iv) glycosomal glyceraldehyde-3-phosphate dehy-
drogenase (TbGAPDH; P22512) (Table S1). Two proteins, TbGK
and TbGAPDH, were selected for further studies as putative
targets of B6, while tubulins were excluded because of the fact that
they are well known to interfere with affinity chromatography
studies due to their high abundance [48]. Indeed, unspecific
association of T. b. brucei tubulin with affinity matrix has been
observed in a similar affinity work by Mercer et al. [49].
Chemical validation of the putative targets TbGK and
TbGAPDH
For the chemical validation of both TbGK and TbGAPDH as
putative targets of B6, the proteins were recombinantly expressed
and purified to near-homogeneity. After purification of TbGK the
SDS-PAGE analysis revealed a band of apparent high purity and
with a subunit molecular weight corresponding to that of TbGK
(56 kDa) (Fig. 2A). The purified protein indeed possessed TbGK
activity, which was inhibited by B6 with an IC50 value of
0.9060.30 mM (Fig. 3A).
Expression and purification of TbGAPDH afforded pure and
active enzyme exhibiting the expected subunit weight of 42 kDa
(Fig. 2B). The inhibition assay showed that B6 was also a good
inhibitor of this enzyme, with an IC50 value of 7.2561.62 mM
(Fig. 3B), strongly indicating that TbGAPDH interaction with
immobilized compound 1 indeed was specific, and that
TbGAPDH was not retained due to its well-known tendency to
be isolated by non-specific association with chromatography resins
[26].
These experiments confirmed the chemical proteomics results.
In fact, both TbGK and TbGAPDH could be inhibited by B6,
and therefore both represent possible molecular targets of this
naphthoquinone derivative.
Glycolysis modeling to investigate the role of GAPDH
and GK
To investigate the metabolic effect of combined and separate
non-competitive inhibition of GAPDH and/or GK, we performed
simulations with the bloodstream-form T. brucei glycolysis model,
based on the Lister 427 strain [30]. Inhibition of GAPDH and GK
together has a strong effect on the ATP production flux (Fig. 4A).
Earlier results showed that 20–40% inhibition of glycolytic ATP
production flux will result in 50% inhibition of the growth rate
[50]. In the simulations, 40% inhibition of the ATP production
flux is reached at an inhibitor concentration of 7 mM. This is only
3.5-fold lower than the experimentally determined ED50 of
24.8 mM for B6 on cultured bloodstream-form Lister 427
trypanosomes (see Methods and below for details). Modeling the
inhibition of GAPDH or GK separately for aerobic glycolysis
showed that GAPDH inhibition alone could be sufficient for the
full effect (Fig. 4A). This can be expected from the fact that under
aerobic conditions, there is only a small flux to glycerol. However,
under anaerobic conditions, glucose is broken down to equimolar
amounts of pyruvate and glycerol [50]. Therefore, we also did
simulations under anaerobic conditions. In this context, B6 had an
even a stronger effect (Fig. 4B), but now GK inhibition alone
would give an equally strong effect on the ATP production flux as
the combined inhibition of GAPDH and GK. We conclude, based
on the modeling, that inhibition of GK is therefore only important
when the parasite experiences periods of low oxygen tension.
Under aerobic conditions prevailing in most part of the blood
circulation system, the non-competitive inhibition of GAPDH
should be sufficient for maximal effect of B6. Therefore, we further
focused on the effect of B6 on GAPDH.
Mechanism of TbGAPDH inhibition
Kinetic studies were performed to investigate the mechanism by
which B6 inhibits TbGAPDH. Figure 5 shows TbGAPDH activity
with respect to NADH (Fig. 5A) or 3-PGA (Fig. 5B) as substrate
and at increasing concentrations of inhibitor B6. Double
reciprocal plots showed B6 to act as a non-competitive inhibitor:
the fitted Ki was similar when NADH or 3-PGA was varied (Ki of
3.6060.57 mM for variation of NADH and Ki of 4.9961.70 mM
for variation of 3-PGA, exhibiting an a value of 0.6 and 0.4,
respectively). The factor a describes the effect of the inhibitor on
Figure 2. Protein identification. (A) SDS-PAGE analysis of purified TbGK. CE: crude extract after lysis in a French Press; IF: insoluble fraction; CCE:
soluble fraction; FT: flow-through; F14–23: fractions of eluted protein. (B) SDS-PAGE analysis of purified TbGAPDH. CCE: crude extract after lysis in a
French Press; IF: insoluble fraction; FT: flow-through; W1–2: washes; F1–3: fractions of eluted protein.
doi:10.1371/journal.pntd.0002012.g002
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the affinity of the substrate toward the enzyme and the effect of the
substrate on the inhibitor affinity for the enzyme [51].
We measured the IC50 value of B6 after a pre-incubation of
TbGAPDH with the inhibitor for 10 min and then diluted them
10-fold to the final concentration for the assay. After 1:10 dilution,
the compound was able to inhibit TbGAPDH with an IC50 value
close to that obtained under standard assay conditions
(IC50 = 9.9863.53 mM with dilution and IC50 = 7.2561.62 mM
without dilution; see Fig. 3B). The long pre-incubation time
necessary for any B6 effect and the observation that IC50 value is
not significantly affected by dilution suggested a possible tight or
covalent binding inhibition mechanism for the compound [52].
A possible explanation for this behavior could be related to the
cysteine trap mechanism of naphthoquinones previously reported
for similar compounds [53]. In particular, we might hypothesize
that B6 could trap Cys166, which has been shown to play a crucial
role in GAPDH’s catalytic activity [54]. However, we cannot rule
out that based on the observed non-competitive inhibition kinetics,
B6 binds GAPDH outside the catalytic pocket. To investigate the
possible covalent bond interaction, we tried to detect the B6/
GAPDH complex by ESI-TOF and MALDI-TOF mass spectros-
copies. However, this peptide fragment was not ionized enough to
be detected by mass spectrometry under our test conditions (data
not shown). Since mass-spectroscopic analysis was not helpful for
clarification of the covalent bonding interaction between Cys166
and B6, we next exploited molecular docking to predict the
plausible binding mode of B6 in the GAPDH active site. A docking
simulation was performed using B6 and the available three-
dimensional structure of TbGAPDH. The docking results (Fig. 6A)
clearly showed that B6 could be suitably placed in the TbGAPDH
active site to undergo a nucleophilic attack from the Cys166 side
chain, and consequently form a covalent adduct, which can be
responsible for the overall inhibition mechanism of B6. In
Figure 6B, two possible mechanisms by which the covalent adduct
Figure 3. Inhibition of the targets by B6. (A) Representative dose-response curve for the inhibition of TbGK by B6. The mean IC50 was found to
be 0.960.3 mM. (B) Representative dose-response curve for the inhibition of TbGAPDH by B6 under standard conditions with the standard deviation
for each point of the curve (blue curve). The IC50 was found to be 7.2561.62 mM. Representative dose-response curve for the inhibition of TbGAPDH
by B6 after dilution 1:10 of enzyme and inhibitor (red curve). The IC50 value was 9.9863.53 mM, which is very close to that measured in the standard
assay, demonstrating that B6 could act as a tight binder.
doi:10.1371/journal.pntd.0002012.g003
Figure 4. Steady-state ATP production flux in a computer model of glycolysis of bloodstream-form T. b. brucei. Steady-state ATP
production flux was calculated by the model at different inhibitor concentrations relative to the uninhibited state. Inhibition was modeled as non-
competitive inhibition with the inhibition constants reported here (Ki GAPDH=4 mM, Ki GK= 0.9 mM) for GAPDH and GK together (N), for GAPDH
alone (#) or for GK alone (,). Simulations were done under aerobic (A) or anaerobic (B) conditions.
doi:10.1371/journal.pntd.0002012.g004
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could be formed are shown. The Cys166 thiol undergoes 1,4-
Michael addition to B6 to form the corresponding thioether-
substituted hydroquinone. Alternatively, a reaction at C3 with the
phenate displacement as leaving group and formation of the
substitution product may take place. Both of these mechanisms
have already been reported for phenoxybenzoquinone derivatives
as VEGFR inhibitors [53].
Inhibition of procyclic cell growth by B6 in the presence
and absence of glucose
Tests of growth inhibition by B6 were performed on procyclic
trypanosomes cultured in medium containing glucose (SDM79
medium), resulting in glycolytic activity for the cells’ main energy
supply, or without glucose (SDM80 medium), where the proline is
the main substrate for free energy production through mitochon-
drial metabolism. Under these latter conditions, the glycosomal
GAPDH would still be needed for gluconeogenesis, to synthesize
glucose 6-phosphate for production of glucoconjugates, but the
gluconeogenic flux is assumed to be much lower than the
glycolytic flux when glucose is present.
It was observed that cells grown under the condition of active
glucose metabolism were somewhat more susceptible for inhibition
by B6 (ED50 = 0.2560.09 mM) than the cells relying on proline
metabolism as their main source of free energy
(ED50 = 0.6760.16 mM). This is in support of our observation
that TbGAPDH, a crucial enzyme of the trypanosomal glycolytic
pathway, may be an intracellular target of B6. Although this
difference in ED50 values is relatively small, it may still be
significant. In addition, the difference between ED50 and IC50
values (see previous paragraph), may suggest that there should be
Figure 5. Kinetic analysis of the inhibition mechanism of B6 on TbGAPDH. The two panels show representative plots of 1/v vs. 1/[NADH] (A)
and 1/v vs. 1/[3-PGA] (B) at different inhibitor concentrations. B6 behaves as a non-competitive inhibitor (mixed type) with respect to NADH and 3-
PGA, exhibiting an a value of 0.6 and 0.4, respectively. The factor a describes the effect of the inhibitor on the affinity of the substrate toward the
enzyme and the effect of the substrate on the inhibitor affinity for the enzyme [51].
doi:10.1371/journal.pntd.0002012.g005
Figure 6. Inhibition mechanism hypothesis. (A) The best-ranked docking pose of B6 at TbGAPDH active site. Cysteine 166 is a key amino acid in
the active site and might covalently bind B6 after a nucleophilic attack of the thiolate to the quinone. (B) Possible mechanism of covalent bond
formation via Michael reaction or nucleophilic substitution.
doi:10.1371/journal.pntd.0002012.g006
Multi-Target Anti-Trypanosomal Compounds
PLOS Neglected Tropical Diseases | www.plosntds.org 8 January 2013 | Volume 7 | Issue 1 | e2012
another target, which plays an important role in causing B6’s
trypanocidal activity.
The effects of B6 on oxygen consumption in T. brucei
Naphthoquinones have been shown to be able to generate free
radicals (mainly ROS) at the mitochondrial level [55]. To
determine whether B6 could exert its trypanocidal action also
through this mechanism, respiration was monitored in permeabi-
lized T. b. brucei bloodstream-form cells in the presence of B6 and/
or SHAM (Fig. 7). SHAM is an inhibitor of TAO, which acts as
the final electron acceptor in bloodstream form T. b. brucei. The
differences in absolute oxygen consumption rate with 10 mM G3P
as electron donor between individual experiments are probably
due to different extents of permeabilization, and hence we also
included the results in percentages (Fig. 7B–D, lower panels). As
expected, 2 mM SHAM inhibited respiration completely (Fig. 7A–
B).
When B6 was added to permeabilized T. b. brucei respiring on
G3P, the oxygen consumption rate increased. This happened both
in the absence and presence of SHAM (Fig. 7A–C), showing that
B6 is not just relieving SHAM inhibition. The oxygen consump-
tion in the presence of SHAM plus B6 was the same irrespective of
whether B6 was added after or together with SHAM (compare
Fig. 7B and D). Clearly, B6 resulted in non-TAO mediated oxygen
consumption. This finding might be explained by taking into
account the capability of B6 to react with molecular oxygen, likely
Figure 7. Oxygen consumption in permeabilized T. b. brucei bloodstream-form cells. (A) Oxygen traces of 26107 digitonin-permeabilized
T. b. brucei bloodstream-form cells. The left panel shows oxygen consumption on G3P for 20 min., while the right panel shows that the additions of
inhibitors were followed for 4–5 min. (B–D) Oxygen consumption rates after serial addition of substrates and compounds within one experiment as
indicated below the X-axis. After addition of the permeabilized cells to the oxygraph, 4–5 successive additions of substrate or inhibitor to the same
incubations were done. After each addition, the oxygen consumption was followed for 4–5 min. before the next addition was done to the same
incubation. The oxygen consumption flux in the 4–5 minutes after each addition was calculated from the trace and plotted. The first addition is
always the substrate G3P and the other additions are inhibitors (B6 or SHAM). Upper graphs show absolute oxygen consumption fluxes, lower graphs
in the same panel show the same results but then relative to the flux on only the substrate G3P in that experiment (i.e. the flux after addition 1). In
each panel, a specific symbol in the graphs denotes a separate experiment throughout the subsequent additions in this experiment. Lines display the
average for the independent experiments (for n$2). G3P= glycerol-3-phosphate, SHAM= salicylhydroxamic acid (inhibitor of the alternative oxidase).
doi:10.1371/journal.pntd.0002012.g007
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as a consequence of ROS production. Addition of an extra 2–
4 mM SHAM did not relieve this B6-mediated oxygen consump-
tion (Fig. 7B–D).
Mitochondrial ROS production
To prove the capability of B6 to generate ROS, we measured
the production of radicals during respiration in a mitochondrial
fraction of T. b. brucei (bloodstream form) in the presence and
absence of B6 (Fig. 8). Indeed, in this experiment, production of
ROS, due to the reactivity of B6 when it was reduced by the
mitochondrial FAD-dependent glycerol-3-phosphate dehydroge-
nase, was detected. After 40 min, B6, in the presence of G3P, was
able to generate radicals in a significant way compared to the
control experiments.
Additional support to prove ROS production as a further
mechanism of action of B6
B6 caused a considerable production of ROS during the
respiration of T. b. brucei bloodstream-form mitochondria, but not
in bovine heart submitochondrial particles (Table S2 and Fig. S1).
To provide support for the notion that the trypanocidal effect of
B6 could in part be attributed to the generation of toxic ROS, we
made use of an available bloodstream form T. b. brucei cell line in
which glucose-6-phosphate dehydrogenase (G6PDH) expression
can be knocked down by RNA interference (RNAi) [56].
Previously, it has been shown that this cell line grows equally
well as wild-type cells under normal (reducing) growth conditions,
but it is highly susceptible to ROS when the G6PDH expression is
partially knocked down, an effect attributed to decreased NADPH
production [57]. Indeed, administration of B6 to cells induced for
decreased expression of G6PDH by RNAi showed that these cells
are much more susceptible. The ED50 for the induced RNAi cell
line is 0.25 mM, whereas for the non-induced RNAi cell line, it was
10.8 mM. This clearly showed that B6 could increase mitochon-
drial ROS production as a further molecular mechanism at the
basis of its trypanocidal profile.
Discussion
Neglected tropical diseases are a huge health emergency, which
requires remarkable efforts in the search for novel drug candidates
to combat them. In fact, the drug discovery pipeline in the field of
neglected tropical infectious diseases is almost dry, and fast
technologies should be exploited to identify novel classes of
potential drug candidates. A possible integrated strategy could be
the use of parallel synthesis to generate libraries of small organic
molecules combined with fast phenotypic assays that allow testing
hundreds of compounds in a reasonable amount of time. This
strategy could rapidly provide new hit candidates that can be
further progressed to the hit-to-lead and lead optimization steps of
the drug discovery process. Thus, it is currently considered equally
productive as the target-based approach [58] and it also show
higher strengths when searching for multitarget ligands [13].
However, to rationally carry out the two latter steps, information
on the molecular target(s), and possibly on the hit-target binding
mode can be of paramount importance, as any modification on
the hit scaffold can be rationally guided by computational and
biophysical/biochemical methods. Therefore, once a hit com-
pound has been identified by means of cell-based experiments, it is
fundamental to try identifying the potential target(s) by means of
bioanalytical approaches. In this respect, chemical proteomics has
emerged as a promising method to fish out targets from cell lysates
using affinity chromatography [26]. Indeed, chemical proteomics
has been shown to be highly suitable in complementing cell-based
experiments, and to provide fundamental information for accel-
erating, in a rational manner, the progress of new classes of
compounds through the drug discovery process [59–61]. It should
be noted that such an approach can be particularly suited for
compounds that form covalent adducts or bind tightly to protein
targets. In addition, non-protein targets (e.g. radical oxygen
production, DNA, etc.) can be missed by using this approach.
Here, we have reported on the application of chemical
proteomics techniques aiming at the identification of the potential
molecular targets of a new class of naphthoquinone derivatives.
They have recently been characterized, by means of cell-based
experiments, to act as trypanocidals, but the molecular target(s) of
this class of compounds remained undisclosed. We have here
identified two potential targets (TbGAPDH and TbGK) of B6, a
representative member of this class of compounds. Subsequent
biochemical assays have clearly demonstrated that B6 is able to
inhibit both targets with IC50 values in the micromolar range.
However, mathematical modeling has shown that GK inhibition
contributed to B6 trypanocidal activity only under low oxygen
conditions. In fact, this enzyme under most physiological conditions
does not play an essential role in the trypanosome’s metabolism, and
is thus considered as a sub-optimal drug target, which may become
important when inhibited in conjunction with other enzymes (i.e.
TAO) [62]. Conversely, GAPDH is a vital parasitic enzyme and a
well-validated molecular target for antiparasitic drug discovery [62].
To fully account for the nanomolar profile of B6 as assessed by
phenotypic cell-based assay, other mechanisms had to be evoked. In
light of this, and based on a vast literature reporting that quinones
and naphthoquinones can interact with the mitochondrial respira-
tory chain [55,63–65], we have performed further experiments
using trypanosomal isolated mitochondria and permeabilized cells.
In this way, we could demonstrate that B6 was also able to interfere
with the respiratory chain by generating ROS, and supporting the
likelihood that B6 interacts with additional targets located in T.
Figure 8. Effect of B6 addition on ROS production by respiring
T. b. bruceimitochondria. Data were obtained evaluating the DCFDA
fluorescence after 1 h in the presence and in the absence of B6 and
G3P.
doi:10.1371/journal.pntd.0002012.g008
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brucei’s mitochondrion. We also observed an ED50 of B6 for
bloodstream-form T. b. brucei strain Lister 427 of 24.8 mM, whereas
the ED50 of procyclics of the same strain grown with glucose as free-
energy source is 0.25 mM. The fact that glucose-grown procyclic
trypanosomes are 100-fold more susceptible than glucose-grown
bloodstream-form cells strongly suggests that in procyclic trypano-
somes inhibition of the glycosomal GAPDH is not the dominant
cause of death. The nature of the dominant target of B6 in the
procyclics, other than GAPDH, remains to be determined. An
alternative possibility is that the bloodstream-form, whose natural
habitat is the human body, expresses a more elaborate system to
deal with ROS generated by the host than the procyclics that live in
the insect’s midgut. Consequently, if B6 generates important ROS
in cells of both life-cycle stages, the cultured bloodstream-forms may
also be better equipped to deal with it than the cultured procyclic
cells. In addition, ROS production might be higher in procyclics, as
respiratory chain complexes I and III, which are well-known sites of
ROS production, are not expressed in the bloodstream forms of T.
brucei. As for GK, its inhibition likely only marginally contributed to
the final trypanocidal activity of our compound. However, glycerol
may be an additional substrate in the blood and, although of much
less use than glucose (lower concentration, and lower ATP yield),
glycerol consumption may relieve the effect of glycolysis inhibition.
In this respect, inhibition of GK by B6 may have relevance in vivo as
it might prevent temporal rescue of the parasite by glycerol
utilization or under transient anaerobic condition.
In conclusion, naphtoquinones like B6 can be considered a
promising class of natural-like multitarget compounds against T.
brucei, which warrants further studies to definitely elucidate its
multitarget profile against parasitic protists.
Supporting Information
Figure S1 Effect of B6 addition on ROS production by
respiring bovine heart submitochondrial particles. Data
were obtained evaluating the DCFDA fluorescence after 1 hour in
presence and absence of B6. B6 effect on the ROS production in SMP
is compared with ROS production induced by 2 mM rotenone.
(PPTX)
Table S1 Results from protein analysis by LC/ESI/
MS/MS-QTOF after direct tryptic digestion of affinity
and control matrices. LC separation using two different
gradients (gradient A and B) and subsequent mass spectrometry
and database searches provided with the probability of 95% for
trypanosome proteins that were absent in the control matrix (ac)
but were present in the matrix coupled with compound 1 (av). The
corresponding proteins are indicated by arrows. The numbers in
the colored boxes correspond to the number of peptide spectra
recorded for a hit. The direct analysis of matrix beads led to
identification of 4 potential targets in (av), which were not found in
the control experiment (ac).
(PPTX)
Table S2 B6 effect on NADH-O2 and succinate-O2
activity in bovine heart submitochondrial particles
(SMP). O2 consumption in SMP (40 mg/ml) was induced by
addition of 150 mM NADH or 10 mM of succinate in the presence
and in the absence of 20 mM of B6.
(PPTX)
Acknowledgments
We are grateful to Dr. Federica Lizzi and Marijke Wagner for technical
assistance, to the team of Dr. P. Hunziker from the Functional Genomics
Center operated by the Swiss Federal Institute of Technology Zurich, and
the University of Zurich for excellent service. We thank Prof. Hans V.
Westerhoff for facilitating trypanosome culture and the oxygraph
experiments at the Vrije Universiteit Amsterdam. We thank Dr. M. T.
Molina (Instituto de Quı´mica Me´dica, CSIC, Spain) for a generous gift of
2-bromo-5-hydroxy-[1,4]-naphthoquinone and 2-bromo-8-hydroxy-[1,4]-
naphthoquinone. We thank Grace Fox for editing and proofreading the
manuscript.
Author Contributions
Conceived and designed the experiments: RP PAMM MLB AC.
Performed the experiments: SP JRH MM RP FP CB RB. Analyzed the
data: JRH RP RF GL GC BMB PAMM LS MLB AC. Contributed
reagents/materials/analysis tools: GL GC PAMM LS MLB AC. Wrote the
paper: JRH PAAM MLB AC.
References
1. Yamey G, Torreele E (2002) The world’s most neglected diseases. BMJ 325: 176–177.
2. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, et al. (2003) The
trypanosomiases. Lancet 362: 1469–1480.
3. Fevre EM, Wissmann BV, Welburn SC, Lutumba P (2008) The burden of
human african trypanosomiasis. PLoS Negl Trop Dis 2: e333.
4. Stuart K, Brun R, Croft S, Fairlamb A, Gurtler RE, et al. (2008) Kinetoplastids:
related protozoan pathogens, different diseases. J Clin Invest 118: 1301–1310.
5. Brun R, Blum J, Chappuis F, Burri C (2010) Human African trypanosomiasis.
Lancet 375: 148–159.
6. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007)
Control of neglected tropical diseases. N Engl J Med 357: 1018–1027.
7. Collins MH, Craft JM, Bustamante JM, Tarleton RL (2011) Oral exposure to
Trypanosoma cruzi elicits a systemic CD8(+) T cell response and protection
against heterotopic challenge. Infect Immun 79: 3397–3406.
8. Castillo E, Dea-Ayuela MA, Bolas-Fernandez F, Rangel M, Gonzalez-Rosende
ME (2010) The kinetoplastid chemotherapy revisited: current drugs, recent
advances and future perspectives. Curr Med Chem 17: 4027–4051.
9. Pink R, Hudson A, Mouries MA, Bendig M (2005) Opportunities and challenges
in antiparasitic drug discovery. Nat Rev Drug Discov 4: 727–740.
10. Renslo AR, McKerrow JH (2006) Drug discovery and development for
neglected parasitic diseases. Nat Chem Biol 2: 701–710.
11. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009)
Nifurtimox-eflornithine combination therapy for second-stage African Trypano-
soma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III,
non-inferiority trial. Lancet 374: 56–64.
12. Cavalli A, Bolognesi ML (2009) Neglected tropical diseases: multi-target-directed
ligands in the search for novel lead candidates against Trypanosoma and
Leishmania. J Med Chem 52: 7339–7359.
13. Cavalli A, Lizzi F, Bongarzone S, Belluti F, Piazzi L, et al. (2010)
Complementary medicinal chemistry-driven strategies toward new antitrypano-
somal and antileishmanial lead drug candidates. FEMS Immunol Med
Microbiol 58: 51–60.
14. Jenwitheesuk E, Samudrala R (2005) Identification of potential multitarget
antimalarial drugs. JAMA 294: 1490–1491.
15. Bolognesi ML (2011) Multi-target-directed ligands as innovative tools to combat
trypanosomatid diseases. Curr Top Med Chem 11: 2824–2833.
16. Kayser O, Kiderlen AF, Croft SL (2003) Natural products as antiparasitic drugs.
Parasitol Res 90 Suppl 2: S55–62.
17. Pinto AV, de Castro SL (2009) The trypanocidal activity of naphthoquinones: a
review. Molecules 14: 4570–4590.
18. Salas CO, Faundez M, Morello A, Maya JD, Tapia RA (2011) Natural and
synthetic naphthoquinones active against Trypanosoma cruzi: an initial step
towards new drugs for Chagas disease. Curr Med Chem 18: 144–161.
19. Krohn K, Hussain H, Viqar UA, Ghulam AM, Green IR (2007) Lapachol: An
Overview Arkivoc Special Issue Reviews and Accounts: 145–171.
20. Wink M (2008) Ecological Roles of Alkaloids In: Fattorusso E, Taglialatela-
Scafati O, editors. Modern Alkaloids: Wiley-VCH Verlag GmbH & Co. KGaA.
pp. 1–24.
21. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG (1992) Quinone
chemistry and toxicity. Toxicol Appl Pharmacol 112: 2–16.
22. Wu HQ, Huang ZS, Bu XZ, Shen YD, Zhang ZL, et al. (2005) The molecular
mechanisms involved in the cytotoxicity of alkannin derivatives. Eur J Med
Chem 40: 1341–1345.
23. Turrens JF (2004) Oxidative stress and antioxidant defenses: a target for the
treatment of diseases caused by parasitic protozoa. Mol Aspects Med 25: 211–
220.
24. Bolognesi ML, Lizzi F, Perozzo R, Brun R, Cavalli A (2008) Synthesis of a small
library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone
derivatives bearing anti-trypanosomal and anti-leishmanial activity. Bioorg Med
Chem Lett 18: 2272–2276.
Multi-Target Anti-Trypanosomal Compounds
PLOS Neglected Tropical Diseases | www.plosntds.org 11 January 2013 | Volume 7 | Issue 1 | e2012
25. Nwaka S, Hudson A (2006) Innovative lead discovery strategies for tropical
diseases. Nat Rev Drug Discov 5: 941–955.
26. Kuettel S, Mosimann M, Maser P, Kaiser M, Brun R, et al. (2009) Adenosine
Kinase of T. b. Rhodesiense identified as the putative target of 4-[5-(4-
phenoxyphenyl)-2H-pyrazol-3-yl]morpholine using chemical proteomics. PLoS
Negl Trop Dis 3: e506.
27. Kralova I, Rigden DJ, Opperdoes FR, Michels PA (2000) Glycerol kinase of
Trypanosoma brucei. Cloning, molecular characterization and mutagenesis.
Eur J Biochem 267: 2323–2333.
28. Schelling P, Folkers G, Scapozza L (2001) A spectrophotometric assay for
quantitative determination of kcat of herpes simplex virus type 1 thymidine
kinase substrates. Anal Biochem 295: 82–87.
29. Hannaert V, Opperdoes FR, Michels PA (1995) Glycosomal glyceraldehyde-3-
phosphate dehydrogenase of Trypanosoma brucei and Trypanosoma cruzi:
expression in Escherichia coli, purification, and characterization of the enzymes.
Protein Expr Purif 6: 244–250.
30. Albert MA, Haanstra JR, Hannaert V, Van Roy J, Opperdoes FR, et al. (2005)
Experimental and in silico analyses of glycolytic flux control in bloodstream form
Trypanosoma brucei. J Biol Chem 280: 28306–28315.
31. Olivier BG, Rohwer JM, Hofmeyr JH (2005) Modelling cellular systems with
PySCeS. Bioinformatics 21: 560–561.
32. Bergmeyer HU (1974) Methods of enzymatic analysis. New York: Academic
Press.
33. De Duve C (1964) Principles of tissue fractionation. J Theor Biol 6: 33–59.
34. Biebinger S, Wirtz LE, Lorenz P, Clayton C (1997) Vectors for inducible
expression of toxic gene products in bloodstream and procyclic Trypanosoma
brucei. Mol Biochem Parasitol 85: 99–112.
35. Brun R, Schonenberger (1979) Cultivation and in vitro cloning or procyclic
culture forms of Trypanosoma brucei in a semi-defined medium. Short
communication. Acta Trop 36: 289–292.
36. Lamour N, Riviere L, Coustou V, Coombs GH, Barrett MP, et al. (2005) Proline
metabolism in procyclic Trypanosoma brucei is down-regulated in the presence
of glucose. J Biol Chem 280: 11902–11910.
37. Orhan I, Sener B, Atici T, Brun R, Perozzo R, et al. (2006) Turkish freshwater
and marine macrophyte extracts show in vitro antiprotozoal activity and inhibit
FabI, a key enzyme of Plasmodium falciparum fatty acid biosynthesis.
Phytomedicine 13: 388–393.
38. Brun R, Lun ZR (1994) Drug sensitivity of Chinese Trypanosoma evansi and
Trypanosoma equiperdum isolates. Vet Parasitol 52: 37–46.
39. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R (1997) The Alamar Blue
assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense
and T.b. gambiense) in vitro. Acta Trop 68: 139–147.
40. Vellieux FM, Hajdu J, Verlinde CL, Groendijk H, Read RJ, et al. (1993)
Structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from
Trypanosoma brucei determined from Laue data. Proc Natl Acad Sci U S A
90: 2355–2359.
41. Nemethy G, Gibson KD, Palmer KA, Yoon CN, Paterlini G, et al. (1992)
Energy Parameters in Polypeptides .10. Improved Geometrical Parameters and
Nonbonded Interactions for Use in the Ecepp/3 Algorithm, with Application to
Proline-Containing Peptides. J Phys Chem 96: 6472–6484.
42. Halgren TA (1996) Merck molecular force field. J Comp Chem 17: 490–641.
43. Abagyan R, Totrov M, Kuznetsov D (1994) Icm - a New Method for Protein
Modeling and Design - Applications to Docking and Structure Prediction from
the Distorted Native Conformation. J Comp Chem 15: 488–506.
44. Totrov M, Abagyan R (1997) Flexible protein-ligand docking by global energy
optimization in internal coordinates. Proteins Suppl 1: 215–220.
45. Totrov M, Abagyan R (2001) Protein-ligand docking as an energy optimization
problem. In: Raffa RB, editor. Drug-receptor thermodynamics: Introduction
and applications. 1st ed. New York, NY: John Wiley & Sons. pp. 603–624.
46. Lomenick B, Olsen RW, Huang J (2011) Identification of direct protein targets
of small molecules. ACS Chem Biol 6: 34–46.
47. Sato S, Murata A, Shirakawa T, Uesugi M (2010) Biochemical target isolation
for novices: affinity-based strategies. Chem Biol 17: 616–623.
48. Shiyama T, Furuya M, Yamazaki A, Terada T, Tanaka A (2004) Design and
synthesis of novel hydrophilic spacers for the reduction of nonspecific binding
proteins on affinity resins. Bioorg Med Chem 12: 2831–2841.
49. Mercer L, Bowling T, Perales J, Freeman J, Nguyen T, et al. (2011) 2,4-
Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identifi-
cation of molecular targets by a chemical proteomics approach. PLoS Negl Trop
Dis 5: e956.
50. Haanstra JR, Kerkhoven EJ, van Tuijl A, Blits M, Wurst M, et al. (2011) A
domino effect in drug action: from metabolic assault towards parasite
differentiation. Mol Microbiol 79: 94–108.
51. Copeland RA (2000) ENZYMES: A Practical Introduction to Structure,
Mechanism, and Data Analysis. New York: Wiley-VCH.
52. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery. A guide
for medicinal chemists and pharmacologists. Methods Biochem Anal 46: 1–265.
53. Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, et al. (2005) 2-
(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible
inhibitors of the kinase domain of vascular endothelial growth factor receptor-
2. J Med Chem 48: 7560–7581.
54. Tisdale EJ, Kelly C, Artalejo CR (2004) Glyceraldehyde-3-phosphate dehydro-
genase interacts with Rab2 and plays an essential role in endoplasmic reticulum
to Golgi transport exclusive of its glycolytic activity. J Biol Chem 279: 54046–
54052.
55. Menna-Barreto RF, Goncalves RL, Costa EM, Silva RS, Pinto AV, et al. (2009)
The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are
mediated by mitochondrial dysfunction. Free Radic Biol Med 47: 644–653.
56. Cordeiro AT, Thiemann OH, Michels PA (2009) Inhibition of Trypanosoma
brucei glucose-6-phosphate dehydrogenase by human steroids and their effects
on the viability of cultured parasites. Bioorg Med Chem 17: 2483–2489.
57. Gupta S, Cordeiro AT, Michels PA (2011) Glucose-6-phosphate dehydrogenase
is the target for the trypanocidal action of human steroids. Mol Biochem
Parasitol.
58. Gilbert IH, Leroy D, Frearson JA (2011) Finding new hits in neglected disease
projects: target or phenotypic based screening? Curr Top Med Chem 11: 1284–
1291.
59. Jeffery DA, Bogyo M (2003) Chemical proteomics and its application to drug
discovery. Curr Opin Biotechnol 14: 87–95.
60. Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G (2007) Target
deconvolution strategies in drug discovery. Nat Rev Drug Discov 6: 891–903.
61. Guiffant D, Tribouillard D, Gug F, Galons H, Meijer L, et al. (2007)
Identification of intracellular targets of small molecular weight chemical
compounds using affinity chromatography. Biotechnol J 2: 68–75.
62. Verlinde CLM, Hannaert V, Blonski C, Willson M, Perie JJ, et al. (2001)
Glycolysis as a target for the design of new anti-trypanosome drugs. Drug
Resistance Updates 4: 50–65.
63. Morello A, Pavani M, Garbarino JA, Chamy MC, Frey C, et al. (1995) Effects
and mode of action of 1,4-naphthoquinones isolated from Calceolaria sessilis on
tumoral cells and Trypanosoma parasites. Comp Biochem Physiol C Pharmacol
Toxicol Endocrinol 112: 119–128.
64. Boveris A, Stoppani AO, Docampo R, Cruz FS (1978) Superoxide anion
production and trypanocidal action of naphthoquinones on Trypanosoma cruzi.
Comp Biochem Physiol C 61 C: 327–329.
65. Fato R, Bergamini C, Leoni S, Lenaz G (2008) Mitochondrial production of
reactive oxygen species: role of complex I and quinone analogues. Biofactors 32:
31–39.
Multi-Target Anti-Trypanosomal Compounds
PLOS Neglected Tropical Diseases | www.plosntds.org 12 January 2013 | Volume 7 | Issue 1 | e2012
